Retatrutide: A Research Overview of the Triple-Receptor Agonist

What is retatrutide?

Retatrutide, also known by its development code LY3437943, is a synthetic peptide and one of the most studied investigational compounds in current metabolic research. It belongs to a class often described as multi-receptor agonists, and its defining feature is that it acts on three receptors at once.

This article summarises the published scientific and clinical-trial literature on retatrutide. It is provided for researchers. Retatrutide is an investigational compound that is not approved for medical use anywhere, and Axiom supplies it strictly as a reagent for in vitro laboratory research. Nothing in this article describes, recommends, or implies its use in humans.

The triple-receptor mechanism

What distinguishes retatrutide from earlier compounds in this area is its action on three distinct receptors simultaneously. According to PubMed, it is an agonist of the glucose-dependent insulinotropic polypeptide receptor (GIPR), the glucagon-like peptide-1 receptor (GLP-1R), and the glucagon receptor (GCGR) DOI.

For context, the widely known compounds semaglutide and tirzepatide act on one and two of these receptor systems respectively. Retatrutide's three-receptor profile is the reason it is sometimes informally referred to as a "triple G" agonist, and it is the basis of the considerable scientific interest in the molecule.

What the clinical trials have reported

Unlike many research peptides, retatrutide has been the subject of formal human clinical trials, conducted by its developer Eli Lilly. This is an important distinction: the evidence base here is clinical-trial data, not animal models.

According to PubMed, a Phase 2 randomised, double-blind, placebo-controlled trial published in the New England Journal of Medicine in 2023 studied retatrutide in adults over 48 weeks. The trial reported dose-dependent reductions in body weight across the dose groups studied, with the placebo group showing minimal change. The most common adverse events reported were gastrointestinal, were described as dose-related and mostly mild to moderate, and the trial also noted dose-dependent increases in heart rate that peaked partway through and then declined DOI.

A separate Phase 2 substudy published in Nature Medicine in 2024 examined effects on liver fat in trial participants with metabolic dysfunction-associated steatotic liver disease, reporting significant reductions in liver fat relative to placebo over the period studied DOI.

These are summaries of what the trials measured. They are reported here as scientific findings, not as outcomes anyone should expect or pursue.

Investigational status

This is the central point for anyone handling the compound. According to PubMed, a 2024 review in the European Journal of Clinical Pharmacology described retatrutide explicitly as an investigational drug, noting that Phase 3 trials began in 2023 and that the available evidence at that point was limited to Phase 2 studies which had yet to be proven in a larger population DOI.

In plain terms: retatrutide is still in the clinical development pipeline. It has not been approved by the MHRA, the FDA, or any other regulator for any use. It is not a medicine, not a licensed treatment, and not a supplement. In the United Kingdom it is supplied for laboratory research use only, and Axiom supplies it on exactly that basis.

Why it matters in research

Retatrutide is studied because its three-receptor mechanism represents a distinct pharmacological approach, and because the metabolic and receptor biology it engages is of broad scientific interest. For researchers, it is a compound at the active frontier of its field, with a growing but still-maturing clinical evidence base.

Handling in the research setting

Like other peptides in this category, retatrutide is supplied as a lyophilised powder, reconstituted for laboratory use, and characterised by purity and identity against a certificate of analysis. Standard peptide-handling practices apply: low-temperature storage of the powder, careful reconstitution, and minimising freeze-thaw cycles of any reconstituted solution. Our general handling and storage guidance covers this in detail.

Summary

Retatrutide is an investigational triple-receptor agonist peptide, acting on the GIP, GLP-1 and glucagon receptors, that has been studied in human Phase 2 clinical trials with Phase 3 trials underway. It is one of the most scientifically significant compounds in current metabolic research, and at the same time it is not approved for any medical use and remains experimental. For researchers, that combination of high scientific interest and clear investigational status is precisely why it is handled, and discussed, strictly within a research-use-only context.